Copy Link Print Information

Irinotecan

(Synonyms: (+)-Irinotecan; CPT-11; VAL-413free base)
81 Cited Publications
Customer Review

Based on 81 publication(s) in Google Scholar

Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex.

For research use only. We do not sell to patients.

  • Purity: 99.97%
  • CAS No.: 97682-44-5
  • Formula: C33H38N4O6
  • Molecular Weight:586.68
  • Storage:

    4°C, protect from light

    * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

  • Irinotecan Chemical Structure
    Irinotecan Chemical Structure
  • Experimental Validation Results for Irinotecan
  • Experimental Validation Results for Irinotecan
  • Experimental Validation Results for Irinotecan
  • Experimental Validation Results for Irinotecan
  • Experimental Validation Results for Irinotecan
  • Experimental Validation Results for Irinotecan
  • Experimental Validation Results for Irinotecan
  • Experimental Validation Results for Irinotecan
  • Experimental Validation Results for Irinotecan
  • Experimental Validation Results for Irinotecan
CAS No.: 97682-44-5
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Irinotecan:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Irinotecan

More
Customer Validation & Images
Cell Proliferation/Viability AssayIn Vivo Efficacy StudyIHCWBCell Imaging/StainingIF
  • Cell Proliferation/Viability Assay
  • WB
  • IHC
  • In Vivo Efficacy Study
  • Cell Imaging/Staining
  • In Vivo Efficacy Study
  • IHC
  • IF
  • Cell Proliferation/Viability Assay
  • WB

All Topoisomerase Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Irinotecan Chemical Structure
    Irinotecan Chemical Structure
    1/16
  • 1/16

    Irinotecan purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]

    Customer Validation
     Analysis of drug sensitivity in various SW480 and HCT116 cell lines after 48 h of treatment with with Irinotecan (1 μmol/L).

  • 1/16

    Irinotecan purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]

    Customer Validation
     Irinotecan (1 μmol/L, 48 h). Western blotting assays on caspase-3 and cleaved caspase-3 in SW480-Con/CBX3 cells following chemotherapy.

  • 1/16

    Irinotecan purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]

    Customer Validation
     Irinotecan (50 mg/kg, twice a week, administered intraperitoneally). Immunohistochemical staining of tumor tissues with antibodies against Ki67, NRF2, and GPX2 (low-power view 100×, high-power view 400×, scale bar = 50 μm).

  • 1/16

    Irinotecan purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]

    Customer Validation
     Irinotecan (50 mg/kg, twice a week, administered intraperitoneally). Tumors were measured every two days, and the tumor volumes were calculated. The tumors were excised and weighed 34 days after injection, and representative images of tumors were displayed (bar = 10 mm).

  • 1/16

    Irinotecan purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]

    Customer Validation
     SW480-Con/CBX3 cells were treated with Irinotecan (1 μmol/L) for 8 h and stained with C11 BODIPY (oxidized lipid was stained green) and then detected by both flow cytometry and confocal microscopy. ERTracker Blue-White was used to detect the location of lipid oxidation by confocal microscopy (high-power view 400×, scale bar = 50 μm) (N = 3).

  • 1/16

    Irinotecan purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Apr;14(4):1677-1692. [Abstract]

    Customer Validation
     Irinotecan (25 mg/kg/day) were administered intraperitoneally from Day 0 to Day 4. Tumor volume in the control, CPT/5FU and E. copr groups were recorded daily.

  • 1/16

    Irinotecan purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Apr;14(4):1677-1692. [Abstract]

    Customer Validation
     Irinotecan (25 mg/kg/day) were administered intraperitoneally from Day 0 to Day 4. Expression of PCNA was measured by IHC and quantified by ImageJ in the tumor sections. Scale bar: 100 mm.

  • 1/16

    Irinotecan purchased from MedChemExpress. Usage Cited in: J Pharm Pharmacol. 2023 Apr 7;75(4):523-532. [Abstract]

    Customer Validation
     Irinotecan (CPT11; 20 μM; 48 h) or Etoposide (VP16; 20 μM; 48 h) induces MDA-MB-231 cells cycle arrest significantly.

  • 1/16

    Irinotecan purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2021 May 28;6(1):188. [Abstract]

    Customer Validation
     Irinotecan (10 μM; 0–4 days). Cystine promoted colon cancer resistance to oxaliplatin and irinotecan (CPT-11) in vitro.

  • 1/16

    Irinotecan purchased from MedChemExpress. Usage Cited in: Apoptosis. 2016 Feb;21(2):130-42. [Abstract]

    Customer Validation
     (a) CPT-11 induces cell cycle arrest and apoptosis in RAW 264.7macrophages. a.Western blot analysis of cleaved caspase-3 and PARP levels. (b) CPT-11 induced cell cycle arrest and apoptosis in mouse peritoneal macrophages. Western blot analysis of cleaved caspase-3 and PARP levels in peritoneal macrophages isolated from vehicleand CPT-11-administered mice. (c) Caspase-3 inhibitor z-DEVD-fmk (ZD) attenuates CPT-11-induced loss of GATA6+ peritoneal macrophages in mice. Western blot analy

  • Irinotecan